(Q36081079)

12 August 2017

1 reference

title

Mechanisms of action of newer antibiotics for Gram-positive pathogens (English)

1 reference

12 August 2017

main subject

gram-positive bacteria

0 references

antibiotic

0 references

author name string

Robert Ew Hancock

series ordinal

1

1 reference

12 August 2017

publication date

1 April 2005

1 reference

Lancet Infectious Diseases

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

209-218

1 reference

Novel antibacterial agents for the treatment of serious Gram-positive infections

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

In vitro pharmacodynamic analysis of single daily dosing versus conventional dosing of gentamicin administered with penicillin against Enterococcus faecalis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Molecular mechanisms of antibiotic resistance in gram-positive pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Molecular mechanisms that confer antibacterial drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Emergence of vancomycin tolerance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Inactivation of antibiotics and the dissemination of resistance genes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Oxazolidinone antibacterial agents: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Quinupristin-dalfopristin and linezolid: evidence and opinion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Streptogramin antibiotics: mode of action and resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Mechanism of action of streptogramins and macrolides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

The role of acyl chain character and other determinants on the bilayer activity of A21978C an acidic lipopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Inhibition of membrane potential-dependent amino acid transport by daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Scanning electronmicroscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Resistance studies with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Cationic peptides: effectors in innate immunity and novel antimicrobials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Role of membranes in the activities of antimicrobial cationic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Mechanism of action of oritavancin and related glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Inhibition of peptidoglycan biosynthesis by ramoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Linezolid: the first oxazolidinone antimicrobial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Occurrence and epidemiology of resistance to virginiamycin and streptogramins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Structural basis of Synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Decline of erythromycin resistance of group A streptococci in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

"Colonization pressure" and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

The impact of nosocomial infections on patient outcomes following cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Occurrence and spread of antibiotic resistances in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Multidrug resistance--a sign of the times.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Antibiotic and antiseptic resistance: impact on public health

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

Potential mechanisms of increased disease in humans from antimicrobial resistance in food animals.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970051-7

7 January 2021

10.1016/S1473-3099(05)70051-7

Identifiers

DOI

1 reference

12 August 2017

1 reference